All news

Missed Biogen's Run? What Holders Had To Believe

Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash

Biogen shares trade near US$251 after a 67.2% return over the past year, with the analyst target of US$247.32 implying about 1.3% downside. Ratings split at 22 buy, 12 hold and 1 sell. The Narrative fair value suggests the market has already priced in successful execution of its growth portfolio, including the Apellis acquisition.

Read original source

BIIB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.